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Abstract 
 
Introduction: Prominent plasma cell infiltration in renal allograft biopsies is a rare finding 
which is associated with poor outcome in adult renal transplant recipients. The clinical impact 
of plasma cell rich acute rejection episodes in paediatric renal transplant recipients (pRTR) 
remains unknown. We investigated the frequency and prognosis in pRTR in a retrospective 
case-control study. 
 
Materials and methods: We conducted a retrospective study of plasma cell rich acute 
rejection episodes in pRTR from April 1996 to March 2014. Cases were defined as all pRTR 
with prominent (≥10% of infiltrate) plasma cells in renal transplant biopsies. Cases were 
compared to controls with typical rejection without significant plasma cell infiltration. Cases 
were matched to control cohort for grade of rejection according to Banff classification, age at 
Tx and Tx age at biopsy. 
 
Results: Plasma cell infiltrates were present in 14 of 162 (9%) pRTR, aged 3.2 - 17.5 
(median 13.4) years at time of transplantation, of whom 13 (93%) received deceased donor 
renal transplants. Compared to 14 matched pRTR renal transplant biopsies without 
significant plasma cells, there were no significant differences in type of Tx (LRD vs DD), 
mismatch, CMV/EBV status of recipient and patient ????? at Tx and baseline eGFR. Plasma 
cells were present in case biopsies with a maximal density of 14 - 116 (median 33) plasma 
cells/hpf/x40. Plasma cells were associated with decreased eGFR at biopsy (22 vs 
49mls/min/1.73m2; p < 0.001), despite comparable eGFR four weeks prior to biopsy. Mean 
eGFR post biopsy was significantly lower in patients with plasma cells (25.8 vs 
55.7mls/min/1.73m2; p < 0.001). Plasma cells were associated with significantly increased 
frequency of renal allograft loss (71% vs 7%; p < 0.001) at 0 - 27 (median 2) months after 
biopsy. 
 
Conclusion: Plasma cell rich acute rejection episodes in pRTR are uncommon but associated 
with reduced renal allograft survival. In the future, bortezomib, a proteasome inhibitor which 
induces apoptosis in mature plasma cells, may play a role in patient management. 
 
Introduction 
The treatment and outcome of renal allograft acute rejection episodes in adults and children 
are mainly determined by the histopathological findings according to revised Banff 
classifications. Acute cellular rejection episodes are classified according to three main 
criteria: vasculitis/endothelialitis, tubulitis and interstitial infiltration (1). Interstitial infiltrates 
are mainly composed of T lymphocytes, monocytes and macrophages. Typically, plasma 
cells account for <5% of infiltrating cells in acute rejection episodes (2). During the last 
decade, so called plasma cell rich acute rejection (PCAR) has been reported, referring to 
acute rejection episodes in which plasma cells account for >10% of the graft infiltrating cells.  
To date PCAR has been observed in around 2% of adults with biopsy proven acute rejection 
(3) (2) and has been reported to be associated with poor prognosis compared with standard 
acute rejection with equivalent Banff scoring (4, 5).  
The frequency and prognostic significance of plasma cell rich acute rejection in paediatric 
renal transplant recipients remains unknown.  
We conducted a retrospective case control study of paediatric renal transplant recipients with 
acute rejection episodes, comparing those with plasma cell rich infiltrates with standard acute 
rejection matched for equivalent Banff scoring.  
 
 
  
Materials and methods 
 
Cases were defined as paediatric renal transplant recipients that underwent a renal allograft 
biopsy for acute, chronic or acute on chronic allograft dysfunction frrm April 1996 to March 
2014 who were found to have subjectively prominent plasma cell infiltration noted on the 
transplant biopsy (indicating plasma cells >10% of the graft infiltrating cells). Cases were 
matched to a control cohort of paediatric renal transplant recipients who also underwent 
renal allograft biopsy for the same indications during the same time period at the cntre 
without significant plasma cell infiltration. Cases were matched to control cohort for age at 
Tx, type of Tx, patient age at biopsy and Tx age at biopsy and biopsy score according to the 
revised Banff classification (2007). Patients underwent percutaneous renal biopsy for acute 
allograft dysfunction as demonstrated by acute rise in plasma creatinine ≥10% from baseline, 
or chronic renal allograft dysfunction with slowly rising creatinine.  
We retrospectively collected demographic, clinical data and previous investigation results 
from clinical records. Data obtained included the following: sex of patient, primary diagnosis, 
number of transplants, age at transplant and age at biopsy, age of transplant at biopsy, type 
of transplantation (deceased versus living related donor), mismatch, EBV and CMV of 
recipient and donor at time of transplant, renal biopsy findings, presence of donor specific 
antibodies. Plasma creatinine and eGFR using the Schwartz formula were collected for 
following time points in regards to the biopsy date: baseline (lowest creatinine reached post 
transplantation), 3 months prior, 4 weeks prior, date of biopsy and 4 weeks post biopsy. Data 
on outcome at final follow up were collected.  
Graft loss was defined the requirement of renal replacement therapy. 
 
The revised Banff 2007 working classification of renal allograft pathology were used to define 
AR and Chronic changes (1).  
AR was graded as  I, II, III or borderline “suspicious” for AR with Grade I AR referring to the 
histological finding of interstitial lymphocytic infiltration and tubulitits, Grade II AR with 
endothelialitis, Grade III AR with transmural arteritis and/or arterial fibrinoid change, and 
borderline “suspicious” of AR referring with foci of mild tubulits only  Chronic changes of 
interstitial fibrosis, tubular atrophy, chronic large vessel changes and arteriolar 
hyalinosiswere noted.  Cases with subjectively prominent plasma cell infiltration in the report 
were identified from the records and matched cases reported with similar Banff severity were 
identified. All biopsies were then reviewed blindly and maximal plasma cell counts per high 
power filed (x40 objective) in the most affected areas, were derived. Plasma cells were rare 
in the controls whereas in the cases numerous plasma cells were present, consistent with 
the previously suggested criteria of >10% of infiltrating inflammatory cells in the region.  
Immunosuppression protocol 
Patients in receipt of their first transplant with no history of cytotoxic antibodies received triple 
immunosuppressive therapy with prednisolone, azathioprine or mycophenolate mofetil and 
tacrolimus or ciclosporin as their baseline immunosuppression. There was one patient in the 
control cohort who received asecond deceased donor allograft. This patient received 
quadruple immunosuppressive therapy including the above triple therapy and additional 
treatment with basiliximab. Patients with biopsy proven CAN had azathioprine switched to 
MMF and the calcineurin inhibitor withdrawn or reduced.  
  
 Statistics 
 
All statistics were performed using SPSS version 22 for Mac. Kaplan-Meier survival curves 
were used to examine renal allograft survival for those with and without plasma cell 
infiltrates. Other relevant clinical and laboratory data were compared between cases and 
control cohort using the Mann-Whitney U-test, or the Fishers exact test with significance set 
at p < 0.05. The log-rank test was used for significance testing for the Kaplan-Meier plots of 
renal allograft survival. Ethical approval for was obtained as per local requirements.  
  
Results  
 
General demographics of cases and controls 
Prominent plasma cell infiltrates were present in renal transplant biopsies studied from 14 of 
162 (9%) renal transplant recipients who underwent renal transplant biopsies for 
investigation of acute or chronic allograft dysfunction. Renal transplant recipients with plasma 
cells present were eight male (57 %), median age 13.4 (3.2 – 17.45) years at time of 
transplantation, of whom 13 (93%) received deceased donor renal transplants and all had 
received their first transplant.  
The matched control cohort of 14 renal transplant recipients without increased plasma cells 
were eight male (57 %), median age 12.2 (3.2 – 16.6) years at time of transplantation of 
whom nine (64%) received deceased donor renal transplants and one was re-transplanted.  
The primary pathologies of both groups were typical of paediatric end stage renal failure and 
are summarized in Table 1. 
There were no significant differences between cases and controls in age at transplant, sex 
(type of transplant (LRD vs DD), mismatch, CMV/EBV status of recipient at TX and patient 
and TX age at biopsy and baseline eGFR in mls/min/1.73 m2 (Table 2).  
 
Immunosuppression 
Baseline immunosuppression in cases consisted of Prednisolone, Tacrolimus, Azathioprine 
(n=9) or Prednisolone, Tacrolimus, Mycophenolate Mofetile (MMF) (n=2) or Prednisolone, 
Ciclosporin, Azathioprine (n = 2) or Prednisolone, Tacrolimus, Rituximab in 1 patient who 
had a previous heart and lung transplantation. Within the controls baseline 
immunosuppression was Prednisolone, Tacrolimus, Azathioprine (n=9) or Prednisolone, 
Tacrolimus, Mycophenolate Mofetile (n=1) or Prednisolone, Ciclosporin, Azathioprine (n = 1) 
or Prednisolone, Tacrolimus, MMF, Basiliximab (n=1) or Prednisolone, Tacrolimus, MMF, 
Dacluzimab (n=1) or Prednisolone, Tacrolimus, Azathioprine and iv IG in the one patient who 
received the second transplant.  
 Plasma cells and biopsy findings 
The median age of cases at biopsy was 15.9 (4.9 – 17.9) years, with a transplant age of 
median 18 (4.9 – 106.5) months compared to median age at biopsy of 13.5 (5.6 – 17.6) 
years and median transplant age of 8.7 (0.7 – 103.2) months for controls (STATS??). There 
was no significant difference in number and grade of rejection according to Banff 
classification between cases and controls. In the group with plasma cells one patient had 
plasma cells only and one patient had findings of tubuluinterstitial nephritis, which could not 
be classified within the BANFF criteria (Table 3).  
Plasma cells were present in cases with a median maximal density of 46 (range 14 - 116) 
plasma cells/hpf. Donor specific antibodies were present in 7 (50%) patients (57% Class I, 
29% Class II and 14% Class I and II HLA antibodies) with 57% of them having increased 
titres giving total MFI of 1252 - 7709.  
 
Plasma cells and allograft function 
There was no significant difference in eGFR at baseline (75.9 vs 88.3; p = 0.175), three 
months prior to biopsy (59.3 vs 76.1, p = 0.79) and four weeks prior to biopsy (48.9 vs 63.7; 
p = 0.110) between cases and controls. At the time of biopsy, cases had significant lower  
mean eGFR (22.3 (SD +- 12.9)), compared to controls (mean eGFR 48.8 (SD +- 15.4; 
p<0.001; Table 2)). Four weeks postbiopsy the mean eGFR of cases remained low with 25.7 
(SD +- 16.1) whereas .the mean eGFR of controls improved to 55.7 (SD +- 14.1) and there 
remained a significant difference between the eGFR of cases and controls 4 weeks post 
biopsy. (p < 0.001).  
 
Plasma cells and outcome 
Patients with prominent plasma cells had an increased rate of graft failure (Table 4). Graft 
failure with return to dialysis occurred in 10 (71%) patients with plasma cells versus in one 
(7%) without plasma cells (p < 0.001). One patient returned to PD, eight patients to HD and 
two patients (including the one from the control group) were re-transplanted.  
Time to graft failure was 5 – 95 months (median 24) post transplantation, and 0 – 27 months 
(median 2) post biopsy in the plasma cell group versus 53 months post transplantation and 
14 months post biopsy in the patient without prominent plasma cells. (Figures 1 and 2). 
From the plasma cell group, four  patients had a functioning allograft until final follow up 3 – 
23 months (median 12.5) post biopsy with a mean eGFR of 38.5 (± 11.9). Three patients 
were transitioned to an adult unit with functioning allograft and one patient is still under 
ongoing care within our department.  
From the controls, 13 patients had a functioning allograft until final follow up 2 – 75 months 
(median 45) post biopsy with a mean eGFR of 51.7 (± 20.8). Nine were transitioned to an 
adult unit with functioning transplant and four are under ongoing care within our department.  
 
Patient survival was 93% (13/14) for cases and 100% forcontrols. Death occurred in one 
case at three years and 11 months post transplantation and three years and six months post 
biopsy due to severe sepsis. The patient had a functioning allograft at time of death.  
 
 
 
 
 
  
Discussion: 
 
With this retrospective case control study we have investigated the frequency and outcome 
of paediatric patients with plasma cell rich acute rejection, and have demonstrated that this 
complicates less than 10% of paediatric renal transplant recipients but is associated with a 
significantly increased risk of graft loss.   
 
Plasma cell rich acute rejection is a relatively newly described entity and is characterized by 
the presence of prominent plasma cells as part of the interstitial inflammatory infiltrate.. 
These findings are rare but have been reported with a frequencyof 2-14% of adult cases with 
biopsy proven acute rejection (2) (4) (6) (7). In children there are only case reports reporting 
PCAR in renal transplant recipients (8). We studied paediatric transplant recipients who 
underwent an allograft biopsy for acute, chronic or acute on chronic allograft dysfunction and 
report a prevalence of 9% , which is similar to results reported in the adult population.  
 
Due to the low prevalence of PCAR it is difficult to definepossible risk factors. We did not 
identify any significant preceeding or concurrent events at the time of biopsy that differed 
from cases to controls. In particular, there were no significant differences in the baseline 
immunological criteria (type of transplant and number of HLA mismatches). Within the cases 
more patients were EBV positive at time of transplantation, but this was not a significant 
difference. Plasma cell infiltrates have been reported in association with EBV induced post 
transplantation lymphoproliferative diseases (PTLD) (3), but importantly, none of our patients 
with plasma cell infiltrates developed PTLD subsequently.  Furthermore the plasma cell rich 
cases reported here were not atypical, and showed no other features of PTLD, wherefore a 
relation to EBV infection is very unlikely. None of the other clinical parameters, including age 
of the patient or age of transplant at time of biopsy were significantly different between both 
groups. In adult studies similar findings are reported (2) (5) (9).  
In our paediatric cohort we observed that at the time of biopsy patients with PCAR already 
had significantly reduced eGFR (mean of 22.3 vs 48.8 mls/min/1.73 m2, p<0.001) compared 
to controls. Both groups received standard treatment for rejection according to BANFF 
classification. Four weeks post biopsy the patients with common acute rejections (CAR) 
showed an increase in mean eGFR to 55.6 mls/min/1.73 m2, whereas the mean eGFR of 
cases remained significantly lower at 25.7 mls/min/1.73 m2 (p<0.001). Those findings confirm 
previously reported observations of poor response of PCAR to augmented 
immunosuppression in adult population (9).    
 
The clinical significance and impact on graft survival has only been addressed in view adult 
studies and remains uncertain(2) (4) (5) (7). In one study of 16 patients with PCAR and 17 
controls there was no significant difference in the proportion of grafts lost by one and three 
years of follow- up (50% vs 59% and 63% vs 76%, p = 0.2) or median time from biopsy to 
graft loss (4.5 vs 6 months) between patients with PCAR and controls. In contrast, most of 
the other studies have reported poorer graft outcome and shorter time to graft loss in PCAR. 
For example graft loss of 52% in PCAR vs 20% (p< 0.05) in classical acute rejections with a 
mean of 6.3 vs 21.5 months post biopsy (5) and overall 6 months graft survival rate after 
diagnosis of PCAR of 50% which was significantly lower controls (9). Similar findings with 
significantly more adverse prognosis of the group rich in plasma cells compared to those non 
rich in plasma cells are described elsewhere (7). 
 
In our population, graft loss with return to dialysis occurred in 10 (71%) patients with plasma 
cell infiltrates versus only one (7.1%) patient without plasma cells (p < 0.001). Graft loss 
occurred also significantly earlier post biopsy in cases versus in controls (median two months 
vs 14 months). Furthermore, those patients with PCAR were more likely to develop more 
severe chronic allograft changes with lower eGFRs at final follow up. Similar findings are 
reported in adults, with serum creatinine remaining high in four out of five patients with PCAR 
and surviving graft in one study (9). Overall, data from the adult population and our current 
data strongly suggest that PCAR is associated with significantly worse outcome, independent 
of the severity of rejection according to other standard BANFF criteria.  
In conclusion, the findings have demonstrated that the presence of plasma cell rich infiltrates 
in paediatric renal transplant biopsies is associated with reduced renal allograft survival and 
reduced allograft function in surviving grafts. National and international collaborative studies 
are required to investigate the incidence and significance of plasma cell infiltrates in 
paediatric renal transplant biopsies. In the future, targeted therapies in such cases may play 
a role in patient management. 
 
  
  
Table 1: Underlying diagnosis of patient population 
 
Diagnosis Cases Controls 
CAKUT 7 6 
FSGS 1 2 
Juvenile Nephronophtisis 2 1 
Cong NS 1  
HUS  1 
Bilateral Wilms tumour  1 
MPGN 1  
Bardet - Biedel 1  
St.p. heart lung TX 1  
Unknown aetiology  3 
  
Table 2: Characteristics of 14 patients with plasma cells in renal transplant biopsies in 
relation to 14 patients with no plasma cells in renal transplant biopsies   
 
 
 Cases (n=14) Controls (n=14) p - value 
Age of patient at biopsy (yrs)    
  Median 15.9 13.5 0.21 
  Range 4.8 – 17.9 5.6 – 17.6  
Age of graft at biopsy (months)    
  Median 18.6 8.7 0.14 
  Range 4.9 – 106.5 0.7 – 103.2  
Donor type    
  LRD 1 5 0.165 
  DD 13 9  
HLA mismatch    
  0 antigen 0 2  
  1 antigen 4 0  
  2 antigen 7 6  
  3 antigen 1 4  
  4 antigen 2 2  
Second transplant    
Recipient EBV pos 10 5 0.06 
Recipient CMV pos 3 6 0.23 
Baseline eGFR (ml/min/ 1.73 m)    
  Mean 75.9 88.2 0.175 
  SD 19.9 26.7  
eGFR at biopspy (ml/min/ 1.73 m)    
  Mean 22.3 48.8 < 0.001 
  SD 12.9 15.4  
 
 
 
 
 
 
 
 
  
Table 3: Grade of rejection according to BANFF classification 
 
BANFF classification Cases Controls 
Acute rejection - Borderline 2 3 
Acute rejection – I a 3 3 
Acute rejection – I b 2 1 
Acute rejection – II a 3 3 
Acute rejection – II b 1 1 
Chronic changes  1 3 
Other 2 0 
 
 
 
 
 
 
 
 
Table 4: Outcome 
 
 Cases  Controls   
 Number Percentage Number Percentage P value 
Functioning graft 4 29% 13 93% < 0.001 
Graft loss total 10 71% 1 7%  
< 1mo 2     
> 1mo – 1 yr 5     
> 1 yr 3  1   
 
 
  
  
Figure 1: Kaplan-Meier plot of renal allograft survival at follow-up post-transplant 
 
 
  
 Figure 2 Kaplan-Meier plot of renal allograft survival at follow-up post-biopsy 
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